چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Purpose: Significant impairment in functioning of patients with mental disorders is created. Bipolar disorder is a common and debilitating mental illness that ranks the fifth for the burden of disease among all patients. It is hard to treat the disorder and stabilize patient’s mood for a long-term due to lack of patient compliance, multiple recurrences and severity of the disease. The most common, costly and the deadliest addiction would belong to nicotine which is often neglected and involved people with bipolar disorder. Smoking and consequently mortality rate in psychiatric patients is higher than the population. Methods: The interventional research studied all patients with Bipolar Disorder type I is. Forty randomly selected patients were divided into two groups: Aripiprazole and placebo. The samples were examined two times; at the baseline and after 6 weeks, with Young Mania Rating Scale, and Fagerstrom Test for nicotine dependence. Data were analyzed using the software package SPSS 18 and p-value< 0.05. Results: Aripiprazole Group showed statistically significant difference in reduction in nicotine use between phases of before and after treatment, but it was not true in the placebo group. The intervention group decreased smoking significantly after 6 weeks of treatment, in contrast to the placebo group. Conclusion: Aripiprazole reduces smoking in patients with Bipolar Disorder type I |
| نویسنده | نفر چندم مقاله |
|---|---|
| سپیده هریزچی قدیم | اول |
| اصغر ارفعی | سوم |
| لیلا بنی فاطمه | ششم |
| مصطفی فرح بخش | چهارم |
| سلمان صفی خانلو | پنجم |
| محمدطاهر طیب زادگان | دوم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| 207-Article Text-1015-3-10-20190505 (1) (1).pdf | 1399/07/27 | 609658 | دانلود |
